B-cell prolymphocytic leukemia (B-PLL) in a patient carrying a TP53 deletion and/or mutation defines a specific clinical subset. The presence of TP53 abnormalities is a key factor that shapes the management strategy from the outset.
This protocol addresses patients with B-cell prolymphocytic leukemia confirmed to have a TP53 deletion and/or TP53 mutation. Unlike B-PLL with intact TP53, this population follows a distinct treatment pathway guided by the altered functional status of TP53.
In patients presenting in an indolent early phase, watchful monitoring is a recognised initial strategy — not all patients require immediate active intervention at diagnosis. The full protocol specifies the conditions under which this approach applies and what comes next.
DOI: 10.1182/asheducation-2015.1.361
For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.
For those patients with nonfunctional TP53, alemtuzumab has historically been the mainstay of treatment and, although no longer licensed in CLL, is available via a patient access scheme.
In those patients with either subtype, presenting with an indolent prephase, watchful monitoring is a reasonable approach.
This situation may persist for a number of years without any clear evidence that early treatment intervention will be beneficial.
View source ↗